Tibet Rhodiola Pharmaceutical Holding Co (600211) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Tibet Rhodiola Pharmaceutical Holding Co stock ¥62.40, price ¥40.37, upside +54.6%, quality 72 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥22.76 – ¥56.43 · fair‑value band ¥39.06 – ¥81.12 · the ¥40.37 price screens below the ¥62.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Tibet Rhodiola Pharmaceutical Holding Co in your weekly email
Every Wednesday you see whether Tibet Rhodiola Pharmaceutical Holding Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally.
Show moreShow less
The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection.
It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products.
In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
The company was founded in 1999 and is headquartered in Lhasa, China.
Stock analysis
Tibet Rhodiola Pharmaceutical Holding Co (600211) currently trades at ¥40.37, while our model-based Fair Value estimate is ¥62.40, implying the stock looks roughly 35% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥67.15 per share, and 18 of the 26 models we run sit above the ¥40.37 price.
Bear case: the Asset-Based group reads lowest at ¥6.73, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥39.06 (bear) to ¥81.12 (bull), the price of ¥40.37 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Tibet Rhodiola Pharmaceutical Holding Co reported revenue of 3.0B CNY in FY2025 versus 2.1B CNY in FY2021, a compound +8.4%/yr. Reported net income was 938M CNY in FY2025, compounding +45.6%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 13.0B CNY (≈ $2.0B) Small · P/E ratio 13.2 · P/S ratio 4.51 · EPS (TTM) ¥3.06 · Dividend yield 5.0% · Net margin 33.9% · Return on equity 21.8% · Return on assets (EBIT) 15.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 81 out of 100 (medium confidence).
What moves the price
The share trades about 15% below its 52-week high and 14% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 55%, 600211 screens cheaper than that median.
Fair Value models
Bear¥39.06Fair Value ¥62.40Bull¥81.12
Price ¥40.37 · Upside +54.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.8873 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+29.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.8%
Dividend (yield on the price)5.0%
Per share before 2007divided by the spin-off factor 1.358
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.24.8% vs 23.7%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 31%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −2.7% a year for the price.
Compare Tibet Rhodiola Pharmaceutical Holding Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside+54.6% · Top 25%
Profitability
Return on equity (12 months)21.8% · Top 25%
Return on assets15.0% · Top 25%
Net margin (12 months)33.9% · Top 25%
Operating margin (12 months)28.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−11.5% · Bottom 25%
Dividend yield (12 months)5.0% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)13.2× · Cheaper than median
P/B3.43× · Priciest 25%
P/S (12 months)4.51× · Priciest 25%
Price / free cash flow (fiscal year)12.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tibet Rhodiola Pharmaceutical Holding Co Fair Value". https://www.fairvalue-calculator.com/stock/600211
Frequently asked questions
Is Tibet Rhodiola Pharmaceutical Holding Co (600211) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥62.40 versus a price of ¥40.37, about +55% upside (undervalued).
What is the fair value of 600211?
Our model-based fair value for Tibet Rhodiola Pharmaceutical Holding Co is ¥62.40 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥40.37.
What is the quality score of 600211?
Tibet Rhodiola Pharmaceutical Holding Co has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Our model-based price target is the fair value of ¥62.40 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario ¥39.06, optimistic scenario ¥81.12. It is a calculation from audited fundamentals, not an analyst target.
What is the Tibet Rhodiola Pharmaceutical Holding Co stock forecast for 2026?
Our models put fair value at ¥62.40, about +55% upside versus a price of ¥40.37 (undervalued). Cautious scenario ¥39.06, optimistic scenario ¥81.12. The calculation is refreshed regularly with new filings.
What is the revenue of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Tibet Rhodiola Pharmaceutical Holding Co reported trailing-twelve-month revenue of about 2.9B CNY (latest available figure, as of Nov 6, 2026).
Does Tibet Rhodiola Pharmaceutical Holding Co pay a dividend?
Tibet Rhodiola Pharmaceutical Holding Co currently shows a dividend yield of 5.01% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Tibet Rhodiola Pharmaceutical Holding Co (600211) and when is the ex-dividend date?
Tibet Rhodiola Pharmaceutical Holding Co pays a dividend of ¥2.02 per share a year, a dividend yield of 5.0%. The last ex-dividend date was Sep 15, 2026. The payout ratio is 66.1% of earnings. Free cash flow covers the dividend 1.55 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Tibet Rhodiola Pharmaceutical Holding Co (600211)?
For today's price to be fair in a discounted-cash-flow model, Tibet Rhodiola Pharmaceutical Holding Co would have to grow free cash flow by -1.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 600211 use?
Our models discount Tibet Rhodiola Pharmaceutical Holding Co at 10.4 %: a base by market capitalisation (small), damped by beta 0.22, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tibet Rhodiola Pharmaceutical Holding Co that is -1.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Tibet Rhodiola Pharmaceutical Holding Co (600211) delivered so far?
Over the past 5 years revenue at Tibet Rhodiola Pharmaceutical Holding Co grew +16.5 % a year. The price currently implies free-cash-flow growth of -1.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tibet Rhodiola Pharmaceutical Holding Co (600211) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Tibet Rhodiola Pharmaceutical Holding Co (-1.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The free-cash-flow yield on the price is 7.77 %: that much free cash flow Tibet Rhodiola Pharmaceutical Holding Co produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tibet Rhodiola Pharmaceutical Holding Co it is ¥62.40 per share (as of Nov 6, 2026), against a price of ¥40.37. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 600211 trades below its calculated fair value: price ¥40.37, fair value ¥62.40, a gap of about +55% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600211?
No. The price is what the market pays today (¥40.37); the fair value is what the company's own numbers justify (¥62.40). For Tibet Rhodiola Pharmaceutical Holding Co the two are ¥22.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tibet Rhodiola Pharmaceutical Holding Co worth?
The market values Tibet Rhodiola Pharmaceutical Holding Co at about 13.0B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥40.37; our models calculate a fair value of ¥62.40 per share.
What do the bullish and bearish scenarios say about 600211?
Our models span a range for Tibet Rhodiola Pharmaceutical Holding Co: cautious scenario ¥39.06, base ¥62.40, optimistic ¥81.12 per share (as of Nov 6, 2026, price ¥40.37). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600211?
Tibet Rhodiola Pharmaceutical Holding Co trades at a price-to-earnings ratio of 13.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥62.40 is built from several models across several years. Other multiples: P/B 3.4, P/S 4.5, EV/EBITDA 12.8.
How solid is the balance sheet of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Balance-sheet figures for Tibet Rhodiola Pharmaceutical Holding Co (as of Nov 6, 2026): return on equity 21.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 600211 from its 52-week high?
Tibet Rhodiola Pharmaceutical Holding Co trades at ¥40.37, about 15% below its 52-week high of ¥47.72 and 14% above the low of ¥35.31 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥62.40 is for.
Which stocks are comparable to Tibet Rhodiola Pharmaceutical Holding Co?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tibet Rhodiola Pharmaceutical Holding Co stock attractive at the current price?
The data as of Nov 6, 2026: price ¥40.37, calculated fair value ¥62.40 (+55%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600211 calculated?
We run Tibet Rhodiola Pharmaceutical Holding Co through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥62.40 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Tibet Rhodiola Pharmaceutical Holding Co currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The closing price on Nov 6, 2026 was ¥40.37. Our model-based fair value is ¥62.40, about +55% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tibet Rhodiola Pharmaceutical Holding Co right now?
Solid quality (72/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (¥39.06 to ¥81.12) leaves room in how you read the outcome.
Where does the earnings growth of Tibet Rhodiola Pharmaceutical Holding Co (600211) come from?
Earnings per share at Tibet Rhodiola Pharmaceutical Holding Co grew +24.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.4 %, EBIT margin +16.7 %, tax rate +0.3 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tibet Rhodiola Pharmaceutical Holding Co
How large is the market capitalisation of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The market capitalisation of Tibet Rhodiola Pharmaceutical Holding Co is 13.0B CNY (≈ $2.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The price-to-sales ratio of Tibet Rhodiola Pharmaceutical Holding Co is 4.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Earnings per share at Tibet Rhodiola Pharmaceutical Holding Co are ¥3.06 (price ÷ EPS = P/E 13.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The dividend yield of Tibet Rhodiola Pharmaceutical Holding Co is 5.0% (payout 66.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The net margin of Tibet Rhodiola Pharmaceutical Holding Co is 33.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The return on equity (ROE) of Tibet Rhodiola Pharmaceutical Holding Co is 21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
On an EBIT basis the return on assets of Tibet Rhodiola Pharmaceutical Holding Co is 15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tibet Rhodiola Pharmaceutical Holding Co (600211)?
The operating margin of Tibet Rhodiola Pharmaceutical Holding Co is 28.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Revenue at Tibet Rhodiola Pharmaceutical Holding Co is growing −11.5% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tibet Rhodiola Pharmaceutical Holding Co (600211)?
Earnings per share at Tibet Rhodiola Pharmaceutical Holding Co are growing +6.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Tibet Rhodiola Pharmaceutical Holding Co (600211) hold?
Tibet Rhodiola Pharmaceutical Holding Co holds more cash than debt, 826M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Tibet Rhodiola Pharmaceutical Holding Co in the live analysis
One click puts Tibet Rhodiola Pharmaceutical Holding Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026